Circulating Neuroendocrine Tumor Gene Signature, the NETest, Defines Therapy in GEP-NETs Abstract #1497

Introduction: Early and precise delineation of therapeutic responses are key issues in GEP-NET management. Imaging has limitations in sensitivity while secretory biomarkers e.g., CgA is controversial.
Aim(s): Evaluate whether NETest predicts responses to somatostatin analogs (SSAs) in a prospective clinical trial.
Materials and methods: Test set: n=35 SSA-treated (RECIST-evaluated) to establish cut-offs to differentiate stable from progressive disease. Prospective trial set: n=28 SSA-treated Grade 1 (n=12)/Grade 2 (n=16) GEP-NETs. CgA (ELISA, normal <109ng/ml) and NETest (qRT-PCR with multianalyte algorithmic analyses: scale, 0–100%). Blood was evaluated monthly prior to SSA injection. CT/MRI were undertaken at entry and 6 monthly until progression (RECIST 1.0).
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Keywords: NETest, CgA, PCR

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1212 Circulating Gene Transcript Analysis of Pancreatic NETs
Introduction: PNETs are aggressive with poor survival. Therapeutic agents are available but efficacy determination is limited by imaging insensitivity and the lack of effective blood biomarkers.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: Daniele Alaimo
Authors: Kidd M, Modlin I, Drozdov I, Alaimo D, ...
Keywords: PNET, NETest, PCR
#1485 Validation of a Blood Neuroendocrine Tumor Gene Signature, the NETest, in a Netherlands NET Cohort
Introduction: The CgA has limitations as a monoanalyte biomarker. The introduction of a PCR-based multi-analyte analysis of 51 genes (NETest) has been proposed as more accurate.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr Margot Tesselaar
Authors: Tesselaar M, Korse T, Kidd M, Verbeek W, ...
#1190 Blood Gene Transcript Analysis Predicts 68Ga- SSA-PET/CT Imaging in Neuroendocrine Tumors and Defines Disease Status
Introduction: Limitations of biomarkers and imaging are a concern in the identification of NET status and therapy response.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Bodei L, Kidd M, Modlin I, Drozdov I, ...
#897 A Molecular Multi-Transcript Gene Blood Signature Significantly Outperforms Chromogranin A (CgA) in the Detection of Gut Neuroendocrine Tumors (NETs)
Introduction: A key issue in NET management is the need for a specific and sensitive biomarker to detect disease and assess treatment. CgA is widely utilized but has limitations.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Professor Irvin M Modlin
Authors: Modlin I M, Kidd M, Drozdov I, Alaimo D, ...
Keywords: biomarker, CgA, NET, PCR
#1489 The Clinical Utility of Blood Neuroendocrine Gene Transcript Analysis, the NETest, in Paragangliomas and Pheochromocytomas
Introduction: Diagnosis of disease and identification of progression are critical issues in paraganglioma (PGL) and pheochromocytoma (PCC) management. An accurate blood biomarker that defines tumor biology irrespective of biochemical activity is lacking.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Keywords: NETest, PCR